Product Reports Resources Pricing Login Book a demo

Cognito Therapeutics

Health Tech & Medtech · Cambridge, United States · Founded 2016

Cognito Therapeutics is a medical technology startup that operates in the healthcare sector, specifically focusing on neurodegenerative diseases such as Alzheimer's. The company's mission is to improve the lives of patients suffering from these diseases through the development of novel therapeutics. The company's primary offering is a breakthrough medical device that delivers non-invasive neuromodulation treatment. Neuromodulation is a process that alters nerve activity through the delivery of electrical or pharmaceutical agents directly to a target area. This device has the potential to significantly improve outcomes for patients with neurodegenerative diseases, offering a new hope for treatment. Cognito's business model revolves around the research, development, and commercialization of this proprietary technology. The company's target market includes millions of patients worldwide suffering from neurodegenerative diseases, as well as healthcare providers seeking innovative treatment options. The company generates revenue through the sale of its medical devices and related services. It also stands to benefit from potential partnerships with larger medical device companies and healthcare institutions, as well as from grants and funding for medical research and development. In summary, Cognito Therapeutics is a promising startup in the MedTech space, offering a novel approach to treating neurodegenerative diseases. Its innovative technology and strong leadership team position it well for future growth in the healthcare sector. Keywords: Neurodegenerative Diseases, Alzheimer's, Medical Technology, Neuromodulation, Non-Invasive Treatment, Healthcare Sector, Medical Device, Research and Development, Proprietary Technology, Patient Outcomes.

Investors

9 investors on Cognito Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 5 investors entered at this stage
FoundersX Ventures
Alzheimer's Drug Discovery Foundation
IAG Capital Partners
WS Investments
Starbloom Capital
Series B+ 4 investors entered at this stage
Morningside
Apollo Health Ventures
Benvolio Group
New Vintage Partners

Global footprint

Where Cognito Therapeutics has talent and traffic

Workforce by country
3 countries with
team presence
🇺🇸 United States94.4%
🇨🇦 Canada3.7%
🇪🇸 Spain1.9%
3 countries shown

Talent graph

The shape of Cognito Therapeutics's talent

Dealroom maps Cognito Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

13 team members profilednamed & role-tagged by Dealroom
63 employeestotal headcount
7 executives & foundersidentified by name
DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Cognito Therapeutics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about Cognito Therapeutics

An AI-synthesized read of the highest-engagement posts about Cognito Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cognito Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.